Albumin/somatropin fusion protein

Drug Profile

Albumin/somatropin fusion protein

Alternative Names: Albutropin; Human Growth Hormone Therapy - Teva; Somatropin/albumin fusion protein; TV-1106

Latest Information Update: 20 May 2016

Price : $50

At a glance

  • Originator CoGenesys
  • Developer Teva Pharmaceutical Industries
  • Class Growth hormones
  • Mechanism of Action Somatotropin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Somatotropin deficiency

Most Recent Events

  • 10 May 2016 Teva Pharmaceutical terminates a phase II trial in Somatotropin deficiency (In children, Treatment-naive) in Bulgaria, Belarus, Czech Republic, Greece, Hungary, Romania, Russia, Ukraine, Serbia, Spain, Georgia, Poland, Israel and Turkey (NCT02092077)
  • 01 Apr 2016 Teva terminates a phase III trial in Somatotropin deficiency (In adults) in USA (SC) (NCT02410356)
  • 01 Apr 2016 Teva terminates a phase III trial in Somatotropin deficiency (Treatment-experienced but not on rhGH treatment within the past 12 months, In adults) in USA (SC) (NCT02410343)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top